Donafenib

Drug Profile

Donafenib

Alternative Names: CM 4307

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator Suzhou Zelgen Biopharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Raf kinase inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Hepatocellular carcinoma
  • Phase I/II Colorectal cancer; Gastric cancer; Oesophageal cancer

Most Recent Events

  • 12 Aug 2016 Suzhou Zelgen Biopharmaceuticals plans a phase III trial in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in China (NCT02870582)
  • 12 Aug 2016 Suzhou Zelgen Biopharmaceuticals plans a phase II trial in Thyroid cancer in China (NCT02870569)
  • 01 Mar 2016 Phase-II/III clinical trials in Hepatocellular carcinoma (Inoperable/Unresectable, Late-stage disease, First-line therapy) in China (PO) (NCT02645981)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top